Here are five quick facts about the update:
• Integra LifeSciences now has a “Buy” consensus rating
• The average 12-month price target is $63.71.
• Argus raised the price total from $61 to $72 on March 25.
• Zacks reiterated “neutral” and set the price target at $63 last month.
• The company has a market cap of $2 billion and 50 day moving average of $59.
The company reported revenue at $252 million for the most recent quarter, up 14.2 percent year-over-year. The analysts predict the company will post $3.17 earnings per share in the current fiscal year.
More articles on orthopedic devices:
12 observations on implant materials for the next generation
16 spine devices receive FDA 510(k) clearance in March
Zimmer voluntarily recalls knee device
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
